View More Recent Stories

Feb 16, 2022 04:05PM Oyster Point Pharma To Report Fourth Quarter And Full Year 2021 Financial Results On February 24, 2022
Feb 16, 2022 04:05PM Oyster Point Pharma To Report Fourth Quarter And Full Year 2021 Financial Results On February 24, 2022
Jan 4, 2022 05:08PM Oyster Point Pharma, Inc., Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Jan 4, 2022 05:08PM Oyster Point Pharma, Inc., Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Dec 21, 2021 04:05PM Oyster Point Pharma to Present at Upcoming Investor Conferences in January 2022
Dec 21, 2021 04:05PM Oyster Point Pharma to Present at Upcoming Investor Conferences in January 2022
Dec 15, 2021 09:27AM Oyster Point Pharma Inc. (OYST) Announces Addition To Nasdaq Biotechnology Index
Dec 15, 2021 09:26AM Oyster Point Pharma Announces Addition To Nasdaq Biotechnology Index
Dec 15, 2021 09:26AM Oyster Point Pharma Announces Addition To Nasdaq Biotechnology Index
Nov 30, 2021 07:09PM Oyster Point Pharma to Participate in the Piper Sandler 33rd Annual Healthcare Conference
Nov 30, 2021 07:09PM Oyster Point Pharma to Participate in the Piper Sandler 33rd Annual Healthcare Conference
Nov 24, 2021 07:00AM Oyster Point Pharma Announces Expansion of Executive Leadership Team to Support Commercialization of Tyrvaya™ (varenicline solution) Nasal Spray for the Signs and Symptoms of Dry Eye Disease
Nov 24, 2021 07:00AM Oyster Point Pharma Announces Expansion of Executive Leadership Team to Support Commercialization of Tyrvaya™ (varenicline solution) Nasal Spray for the Signs and Symptoms of Dry Eye Disease
Nov 15, 2021 07:03AM Oyster Point Pharma Inc. (OYST) Announces Publication of ONSET-2 Phase 3 Data on TYRVAYA Nasal Spray
Nov 15, 2021 07:00AM Oyster Point Pharma Announces Publication in Ophthalmology of ONSET-2 Phase 3 Data on TYRVAYAᵀᴹ (varenicline solution) Nasal Spray
Nov 15, 2021 07:00AM Oyster Point Pharma Announces Publication in Ophthalmology of ONSET-2 Phase 3 Data on TYRVAYAᵀᴹ (varenicline solution) Nasal Spray
Nov 9, 2021 07:01AM Oyster Point Pharma to Present Data at the American Academy of Ophthalmology Annual Meeting 2021
Nov 9, 2021 07:01AM Oyster Point Pharma to Present Data at the American Academy of Ophthalmology Annual Meeting 2021
Nov 4, 2021 04:05PM Oyster Point Pharma Reports Third Quarter 2021 Financial Results and Recent Business Highlights
Nov 4, 2021 04:05PM Oyster Point Pharma Reports Third Quarter 2021 Financial Results and Recent Business Highlights
Nov 4, 2021 08:00AM Oyster Point Pharma Announces Patient Savings Program Where Eligible Patients Can Pay as Little as $0 for TYRVAYA™ (varenicline solution) Nasal Spray for the Treatment of The Signs and Symptoms of D
Nov 4, 2021 08:00AM Oyster Point Pharma Announces Patient Savings Program Where Eligible Patients Can Pay as Little as $0 for TYRVAYA™ (varenicline solution) Nasal Spray for the Treatment of The Signs and Symptoms of D
Nov 3, 2021 04:08PM Oyster Point Pharma Inc. (OYST) Announces TYRVAYA is now Available at US Wholesalers
Nov 3, 2021 04:05PM Oyster Point Pharma’s TYRVAYA™ (varenicline solution) Nasal Spray is Now Available at U.S. Regional Wholesalers for Distribution to Pharmacies for the Treatment of the Signs and Symptoms of Dry Ey
Nov 3, 2021 04:05PM Oyster Point Pharma’s TYRVAYA™ (varenicline solution) Nasal Spray is Now Available at U.S. Regional Wholesalers for Distribution to Pharmacies for the Treatment of the Signs and Symptoms of Dry Ey
Nov 2, 2021 04:45PM Oyster Point Pharma to Present Data at the American Academy of Optometry Annual Meeting 2021
Nov 2, 2021 04:45PM Oyster Point Pharma to Present Data at the American Academy of Optometry Annual Meeting 2021
Oct 28, 2021 07:00AM Oyster Point Pharma to Report Third Quarter 2021 Financial Results on November 4, 2021
Oct 28, 2021 07:00AM Oyster Point Pharma to Report Third Quarter 2021 Financial Results on November 4, 2021
Oct 18, 2021 06:58AM Oyster Point Pharma Inc. (OYST) Announces FDA Approval of TYRVAYA Nasal Spray for the Treatment of the Signs and Symptoms of Dry Eye Disease
Oct 18, 2021 06:00AM Oyster Point Pharma Announces FDA Approval of TYRVAYA™ (varenicline solution) Nasal Spray for the Treatment of the Signs and Symptoms of Dry Eye Disease
May 1, 2021 08:00AM Oyster Point Pharma Announces Clinical Data Presentation of OC-01 (varenicline) Nasal Spray for Dry Eye Disease at the Association for Research in Vision and Ophthalmology 2021 Virtual Annual Meeting
May 1, 2021 08:00AM Oyster Point Pharma Announces Clinical Data Presentation of OC-01 (varenicline) Nasal Spray for Dry Eye Disease at the Association for Research in Vision and Ophthalmology 2021 Virtual Annual Meeting
Mar 2, 2021 06:05AM Oyster Point Pharma Inc. (OYST) Reports NDA Filing Acceptance by FDA for OC-01 (varenicline) Nasal Spray
Mar 2, 2021 06:00AM Oyster Point Pharma Announces FDA Acceptance for Filing New Drug Application for OC-01 (varenicline) Nasal Spray for the Treatment of Signs and Symptoms of Dry Eye Disease
Mar 2, 2021 06:00AM Oyster Point Pharma Announces FDA Acceptance for Filing New Drug Application for OC-01 (varenicline) Nasal Spray for the Treatment of Signs and Symptoms of Dry Eye Disease
View More Recent Stories